Seventy‐Two‐Week Real‐World Outcomes of Tralokinumab Treatment for Moderate‐To‐Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity
The Journal of Dermatology · 2026
DOI: 10.1111/1346-8138.70187 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Manami Yoneyama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Pruritus, Exanthema, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Maruho Takagi Dermatology Foundation, Torii Pharmaceutical.
Abstract (Originalsprache)
An anti–interleukin‐13 antibody tralokinumab is effective for atopic dermatitis (AD). However, there are no real‐world studies on its long‐term outcomes in patients stratified by rash and itch severity. To evaluate the effectiveness of 72‐week tralokinumab treatment in 4 groups of AD patients, stratified by baseline investigator's global assessment (IGA) and peak pruritus numerical rating scale (PP‐NRS), we conducted a prospective study of 167 Japanese patients with moderate‐to‐severe AD from October 2023 to October 2025. Patients received tralokinumab every two weeks. Eczema area and severity index (EASI), IGA, and PP‐NRS were assessed at weeks 0, 4, 12, 16, 24, 36, 48, 60, and 72. Data were analyzed separately in 4 groups; IGA 3/PP‐NRS < 7, IGA 3/PP‐NRS ≥ 7, IGA 4/PP‐NRS < 7, and IGA 4/PP‐NRS ≥ 7. Mean EASI and PP‐NRS decreased in all groups through week 72. The rates achieving IGA 0/1, EASI 100, and PP‐NRS ≥ 4‐point reduction were highest in the group with IGA 3/PP‐NRS ≥ 7 (53.6%, 17.9%, and 92.0%) while lowest in that with IGA 4/PP‐NRS < 7 (10.0%, 0%, and 22.2%). Tralokinumab improved rash and itch throughout 72 weeks across all groups stratified by rash and itch severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda
Förderung
- Maruho Takagi Dermatology Foundation
- Torii Pharmaceutical
Zitieren
APA
Yoneyama, M., Hagino, T., Uchiyama, A., Saeki, H., Fujimoto, E., Motegi, S. I., & Kanda, N. (2026). Seventy‐Two‐Week Real‐World Outcomes of Tralokinumab Treatment for Moderate‐To‐Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70187
Vancouver
Yoneyama M, Hagino T, Uchiyama A, Saeki H, Fujimoto E, Motegi SI, et al. Seventy‐Two‐Week Real‐World Outcomes of Tralokinumab Treatment for Moderate‐To‐Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70187
BibTeX
@article{Yoneyama2026,
author = {Yoneyama, Manami and Hagino, Teppei and Uchiyama, Akihiko and Saeki, Hidehisa and Fujimoto, Eita and Motegi, Sei-Ichiro and Kanda, Naoko},
title = {Seventy‐Two‐Week Real‐World Outcomes of Tralokinumab Treatment for Moderate‐To‐Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70187}
}
EUVIMED